3-week therapeutics for MGD equivalent to 6-week treatment in efficacy and adverse eventsMarch 27th 2023
Investigators reported that moderate to severe Meibomian gland dysfunction (MGD) was treated successfully with a 3-week course of weekly oral azithromycin that was equivalent to a 6-week course of oral doxycyclin.
Hypotension: The second modifiable risk factor in glaucomaFebruary 4th 2023
According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.
Decrease in endothelial cell density continues after iris-fixated phakic IOL explantationJanuary 16th 2023
The research team retrospectively studied the long-term corneal endothelial cell changes and visual outcomes after this iris-fixated phakic IOL was explanted in patients with endothelial damage and investigated any potential predictors of endothelial injury.